ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Phase 2a Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of obesity and its associated metabolic complications, among other inflammatory diseases.Mr. Glover welcomes one-on-one meetings with registered participants. WESTON, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “Z ...